Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.510
-0.180 (-6.69%)
Nov 21, 2024, 2:48 PM EST - Market open
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Frederic Cren |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.40 |
| CIK Code | 0001756594 |
| CUSIP Number | 46124U107 |
| ISIN Number | US46124U1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer and Director |
| Frederic Cren | Co-Founder, Chief Executive Officer and Chairman |
| Jean Volatier | Deputy GM and Chief Financial Officer |
| Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Eric Duranson L.L.M. | General Counsel |
| Nathalie Harroy | Head of Human Resources |
| Dr. Kristina Meyer Ph.D. | Executive Vice President and Business Development and Alliance Management |
| Dr. Michael Cooreman | Chief Medical Officer |
| Pascaline Clerc Ph.D. | Executive Vice President of Strategy and Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | SCHEDULE 13G/A | Filing |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 30, 2024 | 6-K | Report of foreign issuer |
| Oct 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 15, 2024 | 6-K | Report of foreign issuer |